- Home
- WY vs INCY Comparison
WY vs INCY Comparison
Compare WY & INCY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WY
- INCY
- Stock Information
- Founded
- WY 1900
- INCY 1991
- Country
- WY United States
- INCY United States
- Employees
- WY N/A
- INCY N/A
- Industry
- WY Real Estate Investment Trusts
- INCY Biotechnology: Commercial Physical & Biological Resarch
- Sector
- WY Real Estate
- INCY Health Care
- Exchange
- WY Nasdaq
- INCY Nasdaq
- Market Cap
- WY 18.0B
- INCY 17.0B
- IPO Year
- WY N/A
- INCY 1993
- Fundamental
- Price
- WY $22.41
- INCY $105.16
- Analyst Decision
- WY Buy
- INCY Buy
- Analyst Count
- WY 8
- INCY 19
- Target Price
- WY $31.00
- INCY $89.19
- AVG Volume (30 Days)
- WY 5.5M
- INCY 2.6M
- Earning Date
- WY 10-30-2025
- INCY 10-28-2025
- Dividend Yield
- WY 3.72%
- INCY N/A
- EPS Growth
- WY N/A
- INCY 3878.02
- EPS
- WY 0.46
- INCY 5.90
- Revenue
- WY $7,072,000,000.00
- INCY $4,813,105,000.00
- Revenue This Year
- WY $0.04
- INCY $19.33
- Revenue Next Year
- WY $3.97
- INCY $10.47
- P/E Ratio
- WY $49.45
- INCY $17.44
- Revenue Growth
- WY N/A
- INCY 18.09
- 52 Week Low
- WY $22.29
- INCY $53.56
- 52 Week High
- WY $32.70
- INCY $103.86
- Technical
- Relative Strength Index (RSI)
- WY 31.62
- INCY 79.78
- Support Level
- WY $22.29
- INCY $91.16
- Resistance Level
- WY $23.72
- INCY $92.86
- Average True Range (ATR)
- WY 0.50
- INCY 3.94
- MACD
- WY -0.09
- INCY 1.49
- Stochastic Oscillator
- WY 15.11
- INCY 98.34
About WY Weyerhaeuser Company
Weyerhaeuser ranks among the world's largest forest product companies. Following the 2016 sale of its pulp business to International Paper, Weyerhaeuser operates three business segments: timberlands, wood products, and real estate. Weyerhaeuser is structured as a real estate investment trust and is not required to pay federal income taxes on earnings generated by timber harvest activities. Earnings from its wood products segment are subject to federal income tax. Weyerhaeuser acquired fellow timber REIT Plum Creek in 2016.
About INCY Incyte Corp.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.